Ridaforolimus Uses, Dosage, Side Effects and more
| Trade Name | Ridaforolimus |
| Generic | Ridaforolimus |
| Ridaforolimus Other Names | Deforolimus, Ridaforolimus |
| Type | |
| Formula | C53H84NO14P |
| Weight | Average: 990.222 Monoisotopic: 989.562943387 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases.
How Ridaforolimus works
Deforolimus inhibits the mammalian target of rapamycin (mTOR), a serine kinase of the phosphatidylinositol-3-kinase (PI3K) family that regulates protein synthesis, affecting cell growth and proliferation. mTOR is a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways which cancer cells need to proliferate.
